Chemotherapy for Merkel Cell Carcinoma with Carboplatin and Etoposide

Pectasides, Dimitrios; Moutzourides, G; Dimitriadis, M.; Varthalitis, J.; Athanassiou, Athanassios

doi:10.1097/00000421-199510000-00011

Cited by 39 publications

(24 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…'7"18 We were unable to demonstrate the value of adjuvant radiotherapy in this series secondary to the low incidence of local recurrence and the infrequent use of adjuvant radiotherapy. 24 Our data have not shown a benefit in the use of chemotherapy in the adjuvant setting. Patients who received adjuvant chemotherapy, both after the initial treatment of disease and after disease recurrence, did not show an improvement in either relapse-free or disease-specific survival.…”

Section: Survival After Recurrencementioning

confidence: 50%

See 1 more Smart Citation

Surgical Management of Merkel Cell Carcinoma

Allen

Zhang²,

Coit³

1999

Annals of Surgery

243

212

View full text Add to dashboard Cite

Section: Survival After Recurrencementioning

confidence: 50%

“…1). At the time of last follow-up, 62 patients were free of disease, 24 patients were dead of disease, 9 were alive with disease, and 7 had died of other causes. …”

Section: Survivalmentioning

confidence: 99%

Surgical Management of Merkel Cell Carcinoma

Allen

Zhang²,

Coit³

1999

Annals of Surgery

243

212

View full text Add to dashboard Cite

“…There are few reports in the literature, with a limited number of patients [3, 13, 27,29,30,31,32,33,34]. The concept of its use was the high rate of response of advanced disease to systemic CT.…”

Section: Discussionmentioning

confidence: 99%

“…In contrast, the role of systemic CT in the treatment of advanced disease is better established [11,32,33,34,37,38,39,40,41]. One of the most studied CT regimens was the combination of a platinum compound, cisplatin or carboplatin, and etoposide.…”

Section: Discussionmentioning

confidence: 99%

Merkel Cell Carcinoma of the Skin: A Retrospective Study of 24 Cases by the Hellenic Cooperative Oncology Group

Pectasides

Papaxoinis²,

Pectasides³

et al. 2007

Oncology

Self Cite

View full text Add to dashboard Cite

Background: The purpose of this retrospective study was to present the epidemiological and clinical characteristics of 24 patients with Merkel cell carcinoma of the skin (MCC) and their response to various therapeutic modalities. Methods: The tumor registry of the Hellenic Cooperative Oncology Group was used to identify patients with MCC diagnosed between 1986 and 2006. Results: The most frequent primary sites were the extremities (50%), followed by the head (33%) and the trunk (17%). Median time of follow-up was 24 months. Sixteen patients were initially diagnosed with stage I, 5 patients with stage II, and 3 patients with stage III (metastatic) disease. Six patients with stage I disease received adjuvant chemotherapy (CT) and/or radiotherapy (RT). All patients with stage I disease treated only with surgery relapsed, whereas 33% of the patients treated with adjuvant therapy recurred. All patients with stage II disease received adjuvant treatment. Among them, 2 patients relapsed. Disease-free survival (DFS) and overall survival (OS) did not differ significantly between patients with stage I and II disease (stage I: 4-year DFS 27%, 4-year OS 56%; stage II: 4-year DFS 60%, 4-year OS 80%). Patients treated with adjuvant therapy had significantly better DFS than those treated only with surgery (p = 0.012), but OS did not differ significantly (adjuvant group: 4-year DFS 59%, 4-year OS 74%; surgery group: 4-year DFS 10%, 4-year OS 50%). Eleven patients with locally advanced or metastatic disease received CT. The response rate was 73% (complete remission 18%), median progression-free survival was 10 months and median OS was 14 months. Complete remission was achieved in 2 other cases, with the addition of RT after CT. Conclusions: MCC is an aggressive neoplasm with significant chemosensitivity and radiosensitivity, but poor outcome. The role of adjuvant treatment should be further investigated.

show abstract

“…A wide variety of chemotherapeutic agents have been used. Cyclophosphamide-and adriamycin-based therapy with or without vincristine or dacarbazine, cisplatinum or carboplatin, octreotide, and etoposide have shown the most promising results [38][39][40][41]. In a review of 107 patients suffering from MCC and treated with chemotherapy, the response rate was between 57 and 61% for patients with metastatic disease [42].…”

Section: Discussionmentioning

confidence: 99%

Merkel Cell Carcinoma: Report of Seven Cases

Karapantzos

Tsaroucha

Polychronidis

et al. 2003

ORL

View full text Add to dashboard Cite

Merkel cell carcinoma (MCC) is an infrequent, highly malignant, primary skin tumor derived from neuroendocrine cells. Most MCCs occur in elderly individuals, on sun-exposed areas of the body, with the head and neck being the most common sites. We present 7 patients (2 male and 5 female, age 45–80 years) suffering from MCC and treated between 1993 and 2000. All tumors were located on the head and neck and varied from 0.9 to 2.3 cm in size. Five of the patients had stage II disease, 1 patient had stage Ia disease and 1 patient had stage III disease. Six of the patients had positive regional lymph nodes. All patients had local excision of the tumor. Six of them also had lymph node dissection and in 5 of them a superficial parotidectomy was performed. Five patients received adjuvant radiotherapy and 3 of them also received chemotherapy. Local and cervical lymph node recurrence was observed in only 1 patient. Metastases occurred in 5 patients. One patient died within 10 days for other reasons. The patient with the stage III tumor had a survival of 7 months. The other 5 patients had survivals varying from 15 to 54 months. MCC is a skin tumor with very poor prognosis and high recurrence and metastatic rates. Its treatment is still under discussion. Radical excision of the tumor is the main method of treatment. Selective lymph node dissection is suggested. Superficial parotidectomy seems necessary, especially if the tumor is on the auricle. Adjuvant radio- and chemotherapy may extend survival in case of small-size tumors.

show abstract

Chemotherapy for Merkel Cell Carcinoma with Carboplatin and Etoposide

Cited by 39 publications

References 0 publications

Surgical Management of Merkel Cell Carcinoma

Surgical Management of Merkel Cell Carcinoma

Merkel Cell Carcinoma of the Skin: A Retrospective Study of 24 Cases by the Hellenic Cooperative Oncology Group

Merkel Cell Carcinoma: Report of Seven Cases

Contact Info

Product

Resources

About